Kavya Keerthana, Hematologist at Prime Health, shared on LinkedIn:
“A new development in CLL treatment: Pirtobrutinib moves into the frontline.
On October 2, 2026, the US FDA approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without known del(17p).
This is an important development in the rapidly evolving treatment landscape of CLL.
The approval was based on the phase 3 BRUIN CLL-313 trial, which enrolled 282 previously untreated patients without del(17p).
Patients received either: Pirtobrutinib – continuously until disease progression vs Bendamustine + rituximab – 6 cycles
At a median follow-up of 28 months:
- Median PFS with pirtobrutinib: not reached
- Median PFS with bendamustine + rituximab: 33.5 months
- Hazard ratio for progression or death: 0.20
- P < 0.0001
In other words, pirtobrutinib produced a substantial reduction in the risk of progression or death compared with the chemoimmunotherapy comparator in this trial.
But Why is pirtobrutinib interesting?
Unlike conventional covalent BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib, pirtobrutinib is a non-covalent (reversible) BTK inhibitor.
This different binding mechanism was developed in part to maintain BTK inhibition even when resistance mutations such as BTK C481 interfere with covalent BTK inhibitor binding.
Pirtobrutinib was already an important drug in relapsed/refractory CLL, particularly after exposure to a covalent BTK inhibitor.
Now, with this new FDA indication, its role is expanding into previously untreated CLL.
But does this mean pirtobrutinib becomes the treatment for every newly diagnosed CLL patient?
No.
CLL treatment is increasingly individualized based on:
- TP53 status / del(17p)
- IGHV mutation status
- Disease biology and burden
- Previous and planned targeted therapies
- Age and comorbidities
- Continuous vs fixed-duration treatment strategies
- Depth of response and MRD
The key question is no longer simply ‘Which chemotherapy should we use?‘
The field has moved decisively toward targeted, biology-driven treatment strategies.”
Other articles about CLL on OncoDaily.